Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Современные возможности лечения дифференцированного рака щитовидной железы, резистентного к терапии радиоактивным йодом: резолюция по итогам Экспертного cовета
________________________________________________
Rumyantsev P.O., Gorbunova V.A., Podviaznikov S.O. Modern therapy of radioactive iodine-refractory differentiated thyroid cancer: resolution of the Expert Council. Journal of Modern Oncology. 2016; 18 (3): 48–51.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: дифференцированный рак щитовидной железы, рефрактерный к терапии радиоактивным йодом, ленватиниб.
________________________________________________
The meeting of experts, concerning the treatment of thyroid cancer was held in Moscow in June 2016. The aim of the meeting was unsolved tasks in the field of therapy of the patients with radioactive iodine-refractory differentiated thyroid cancer. Nowadays, this group of patients still has a poor prognosis with respect to life expectancy. The experts are faced with some difficulties in choosing the treatment tactics in patients after radioiodine therapy have become ineffective and we observe disease progression. And still valid questions remain unsolved: when should doctors stop therapy using radioactive iodine? When should patient start therapy using targeted agents? What kind of targeted agent should specialist choose for treatment of this desiase? How should one manage the developing side effects against the backdrop of targeted therapy? These and some other problems have been discussed within the framework of this counsel.
Key words: differentiated thyroid cancer, radioactive iodine-refractory, lenvatinib.
2. Robbins RJ, Wan Q, Grewal RK et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91 (2): 498–505. doi: 10.1210/jc.2005-1534.
3. NCCN Clinical Practice Guidelines in Oncology. Thyroid Carcinoma Version 2.2015 http://www.nccn.org/professionals/physician_gls/ pdf/thyroid.pdf Последний доступ: 25.11.14.
4. Pacini F, Castagna MG, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ESMO Guidelines Working Group. Ann Oncol 2012; 23 (Suppl. 7): vii 110–9.
5. Perros P et al. Guidelines for the management of thyroid cance. Clin Endocrinol 2014; 81 (S1): 1–22.
6. Schlumberger M, Tahara M, Wirth LJ et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015; 372 (7): 621–30. doi: 10.1056/NEJMoa1406470.
7. Milan A, Puglisi E, Ferrari L et al. Arerial hypertension and cancer. Int J Cancer 2014; 134: 2269–77.
8. Mir O, Ropert S, Alexandre J et al. Hypertension as a surrogate marker for the activity of anti- VEGF agents. Ann Oncol 2009; 20 (5): 967–70.
9. Maitland ML, Bakris GL, Black HR et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596–604.
________________________________________________
1. Durante C, Haddy N, Baudin E et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91 (8): 2892–9. doi: 10.1210/jc.2005-2838.
2. Robbins RJ, Wan Q, Grewal RK et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91 (2): 498–505. doi: 10.1210/jc.2005-1534.
3. NCCN Clinical Practice Guidelines in Oncology. Thyroid Carcinoma Version 2.2015 http://www.nccn.org/professionals/physician_gls/ pdf/thyroid.pdf Последний доступ: 25.11.14.
4. Pacini F, Castagna MG, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ESMO Guidelines Working Group. Ann Oncol 2012; 23 (Suppl. 7): vii 110–9.
5. Perros P et al. Guidelines for the management of thyroid cance. Clin Endocrinol 2014; 81 (S1): 1–22.
6. Schlumberger M, Tahara M, Wirth LJ et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015; 372 (7): 621–30. doi: 10.1056/NEJMoa1406470.
7. Milan A, Puglisi E, Ferrari L et al. Arerial hypertension and cancer. Int J Cancer 2014; 134: 2269–77.
8. Mir O, Ropert S, Alexandre J et al. Hypertension as a surrogate marker for the activity of anti- VEGF agents. Ann Oncol 2009; 20 (5): 967–70.
9. Maitland ML, Bakris GL, Black HR et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596–604.
1 ФГБУ Эндокринологический научный центр Минздрава России. 117036, Россия, Москва, ул. Дмитрия Ульянова, д. 11;
2 ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23;
3 ФГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1;
4 ФГБУ Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России. 117997, Россия, Москва, ул. Саморы Машела, д. 1;
5 Медицинский радиологический научный центр им. А.Ф.Цыба, филиал ФГБУ Национальный медицинский исследовательский радиологический центр Минздрава России. 249036, Россия, Обнинск, ул. Королева, д. 4;
6 ФГАОУ ВО Российский университет дружбы народов. 117198, Россия, Москва, ул. Миклухо-Маклая, д. 6;
7 ГБУЗ Городская клиническая больница №64. 117292, Россия, Москва, ул. Вавилова, д. 61;
*pavelrum@gmail.com
________________________________________________
P.O.Rumyantsev*1, V.A.Gorbunova2, S.O.Podvyaznikov3, N.V.Zhukov4, P.A.Isaev5, V.V.Krylov5, A.M.Mudunov2, A.A.Rodichev5, E.K.Shavarova6,7
1 Endocrinology Research Center of the Ministry of Health of the Russian Federation. 117036, Russian Federation, Moscow, ul. Dmitria Ul'ianova, d. 11;
2 N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 2;
3 Russian Medical Academy of Postgraduate Education, of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1;
4 Dmitriy Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Samory Mashela, d. 1;
5 A.F.Tsyba Medical Radiological Scientific Center, branch of National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation. 249036, Russian Federation, Obninsk, ul. Koroleva, d. 4;
6 People’s Friendship University. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaia, d. 6;
7 City Clinical Hospital №64. 117292, Russian Federation, Moscow, ul. Vavilova, d. 61
*pavelrum@gmail.com